Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi

Yehia Saleh; Abdullah Al-abcha; Ola Abdelkarim; Mahmoud Abdelnabi; Abdallah Almaghraby; Neal S. Kleiman

doi:10.1007/s40256-021-00509-2

Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi

Yehia Saleh, Abdullah Al-abcha, Ola Abdelkarim, Mahmoud Abdelnabi, Abdallah Almaghraby, Neal S. Kleiman

Research output: Contribution to journal › Article › peer-review

Abstract

Left ventricular thrombi form due to the presence of Virchow’s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.

Original language	English (US)
Pages (from-to)	231-238
Number of pages	8
Journal	American Journal of Cardiovascular Drugs
Volume	22
Issue number	3
DOIs	https://doi.org/10.1007/s40256-021-00509-2
State	Published - May 2022

Keywords

Administration, Oral
Anticoagulants/therapeutic use
Atrial Fibrillation/drug therapy
Fibrinolytic Agents/therapeutic use
Humans
Thrombosis/drug therapy
Ventricular Dysfunction, Left/drug therapy
Vitamin K

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1007/s40256-021-00509-2

Cite this

@article{28faae0b02b54eb6a2cb5b8d53ed66f3,

title = "Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi",

abstract = "Left ventricular thrombi form due to the presence of Virchow{\textquoteright}s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.",

keywords = "Administration, Oral, Anticoagulants/therapeutic use, Atrial Fibrillation/drug therapy, Fibrinolytic Agents/therapeutic use, Humans, Thrombosis/drug therapy, Ventricular Dysfunction, Left/drug therapy, Vitamin K",

author = "Yehia Saleh and Abdullah Al-abcha and Ola Abdelkarim and Mahmoud Abdelnabi and Abdallah Almaghraby and Kleiman, {Neal S.}",

note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.",

year = "2022",

month = may,

doi = "10.1007/s40256-021-00509-2",

language = "English (US)",

volume = "22",

pages = "231--238",

journal = "American Journal of Cardiovascular Drugs",

issn = "1175-3277",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi

AU - Saleh, Yehia

AU - Al-abcha, Abdullah

AU - Abdelkarim, Ola

AU - Abdelnabi, Mahmoud

AU - Almaghraby, Abdallah

AU - Kleiman, Neal S.

PY - 2022/5

Y1 - 2022/5

N2 - Left ventricular thrombi form due to the presence of Virchow’s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.

AB - Left ventricular thrombi form due to the presence of Virchow’s triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.

KW - Administration, Oral

KW - Anticoagulants/therapeutic use

KW - Atrial Fibrillation/drug therapy

KW - Fibrinolytic Agents/therapeutic use

KW - Humans

KW - Thrombosis/drug therapy

KW - Ventricular Dysfunction, Left/drug therapy

KW - Vitamin K

UR - http://www.scopus.com/inward/record.url?scp=85118539233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118539233&partnerID=8YFLogxK

U2 - 10.1007/s40256-021-00509-2

DO - 10.1007/s40256-021-00509-2

M3 - Article

C2 - 34738217

AN - SCOPUS:85118539233

SN - 1175-3277

VL - 22

SP - 231

EP - 238

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

IS - 3

ER -

Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this